avibactam: Clinical Trials

7 completed. 7 Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	7	Completed 7

Follow avibactam: new trials by email Literature Review of avibactam trials Research Report on avibactam

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study on Tolerance, Pharmacokinetics and Drug Interaction of YK-1169 in Healthy Volunteers Group 1:YK-1169, Group 2:YK-1169/Placebo Injection, Group 3:YK-1169/Placebo - Pharmacokinetics	Phase 1	Completed	Nanjing Yoko Biomedical Co., Ltd.	66	2021-12-20	2022-10-20
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) Avibactam (AVI), Aztreonam (ATM), combination of Aztreonam - Avibactam (ATM-AVI) - Complicated Infection, Bacterial Infections	Phase 1	Completed	Pfizer	222	2012-09-01	2017-09-06
Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance Ceftaroline fosamil/Avibactam (CXL) - Augmented Renal Clearance (ARC), Systemic Inflammatory Response Syndrome (SIRS)	Phase 1	Completed	Forest Laboratories	12	2012-05-01	2017-04-07
A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately CAZ104, Avibactam, Ceftazidime - Healthy	Phase 1	Completed	Pfizer	43	2011-09-01	2017-09-01
Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma CAZ104 - Healthy	Phase 1	Completed	Pfizer	45	2011-08-01	2017-09-01
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers NXL104, Ceftaroline, Placebo Infusion - Healthy Male Volunteers	Phase 1	Completed	Pfizer	54	2011-02-01	2017-09-01
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects NXL104, CAZ104, Placebo - Healthy Male and Female Japanese Volunteers	Phase 1	Completed	Pfizer	15	2011-02-01	2017-09-01

Conditions studied

Bacterial Infections (1)  ·  Intraabdominal Infections (1)  ·  Systemic Inflammatory Response Syndrome (1)  ·  Urinary Tract Infections (1)

Sponsors

Pfizer (5)  ·  Forest Laboratories (1)  ·  Nanjing Yoko Biomedical Co., Ltd. (1)

Countries

United Kingdom (3)  ·  United States (3)  ·  Australia (1)  ·  China (1)

Top investigators

Paul Newell, MD (4)  ·  Mirjana Kujacic, MD (2)  ·  David Mathews, MD (1)  ·  Frans van den Berg, MD (1)  ·  Leonard Siew, MBCHB (1)  ·  Leonard Siew, MBCHB, MRCP(UK) (1)  ·  Mark Yen, MD (1)

Results publications

PMID 30221827, PMID 24150927, PMID 38252170